Nicole Alexandra Frank1, Ladina Greuter2, Raphael Guzman2,3,4, Jehuda Soleman2,3,4. 1. Department of Neurosurgery, University Hospital of Basel, Basel, Switzerland. franknicolealexandra@gmail.com. 2. Department of Neurosurgery, University Hospital of Basel, Basel, Switzerland. 3. Department of Pediatric Neurosurgery, University Children's Hospital of Basel, Basel, Switzerland. 4. Faculty of Medicine, University of Basel, Basel, Switzerland.
Abstract
INTRODUCTION: Drug-resistant epilepsy occurs in up to 30% of children suffering from seizures and about 10% qualify for surgical treatment. The aim of this systematic review and meta-analysis is to analyze the potential benefit of early epilepsy surgery in children concerning primarily seizure and developmental outcome. METHODS: PubMed and Embase databases were searched using a systematic search strategy to identify studies on pediatric epilepsy surgery under 3 years from their inception up to 2022. Outcome measures were seizure outcome, postoperative complications, seizure onset, and reduction rate of antiepileptic drugs. A meta-analysis was thereafter performed for all included cohort studies. A p-value of < 0.05 was considered as statistically significant. RESULTS: A total of 532 patients were analyzed with 401 patients (75%) receiving resective or disconnective surgery under the age of 3 years and 80 patients (15%) receiving surgery older than 3 years. The remaining 51 patients (9%) underwent VNS implantation. Pooled outcome analysis for resective/disconnective surgery showed favorable outcome in 68% (95% CI [0.63; 0.73]), while comparative analysis between the age groups showed no significant difference (77% early group and 75% late group; RR 1.03, 95% CI [0.73; 1.46] p = 0.75). Favorable outcome for the VNS cohort was seen in 52%, 65% in the early and 45.1% in the late group (RR 1.4393, 95% CI [0.87; 2.4] z = 1.42, p = 0.16). Developmental outcome was improved in 26%. Morbidity rate was moderate and showed no significant difference comparing the age groups, and overall surgical mortality rate was very low (0.1%). CONCLUSION: Epilepsy surgery in pediatric age, especially under the age of 3 years, is a feasible and safe way to treat intractable epilepsy. Further comparative studies of prospective nature, analyzing not only seizure but also developmental outcome, should be the focus of future studies.
INTRODUCTION: Drug-resistant epilepsy occurs in up to 30% of children suffering from seizures and about 10% qualify for surgical treatment. The aim of this systematic review and meta-analysis is to analyze the potential benefit of early epilepsy surgery in children concerning primarily seizure and developmental outcome. METHODS: PubMed and Embase databases were searched using a systematic search strategy to identify studies on pediatric epilepsy surgery under 3 years from their inception up to 2022. Outcome measures were seizure outcome, postoperative complications, seizure onset, and reduction rate of antiepileptic drugs. A meta-analysis was thereafter performed for all included cohort studies. A p-value of < 0.05 was considered as statistically significant. RESULTS: A total of 532 patients were analyzed with 401 patients (75%) receiving resective or disconnective surgery under the age of 3 years and 80 patients (15%) receiving surgery older than 3 years. The remaining 51 patients (9%) underwent VNS implantation. Pooled outcome analysis for resective/disconnective surgery showed favorable outcome in 68% (95% CI [0.63; 0.73]), while comparative analysis between the age groups showed no significant difference (77% early group and 75% late group; RR 1.03, 95% CI [0.73; 1.46] p = 0.75). Favorable outcome for the VNS cohort was seen in 52%, 65% in the early and 45.1% in the late group (RR 1.4393, 95% CI [0.87; 2.4] z = 1.42, p = 0.16). Developmental outcome was improved in 26%. Morbidity rate was moderate and showed no significant difference comparing the age groups, and overall surgical mortality rate was very low (0.1%). CONCLUSION: Epilepsy surgery in pediatric age, especially under the age of 3 years, is a feasible and safe way to treat intractable epilepsy. Further comparative studies of prospective nature, analyzing not only seizure but also developmental outcome, should be the focus of future studies.
Authors: Navah Ester Kadish; Thomas Bast; Gitta Reuner; Kathrin Wagner; Hans Mayer; Susanne Schubert-Bast; Gert Wiegand; Karl Strobl; Armin Brandt; Rudolf Korinthenberg; Vera van Velthoven; Andreas Schulze-Bonhage; Josef Zentner; Georgia Ramantani Journal: Neurosurgery Date: 2019-06-01 Impact factor: 4.654
Authors: C Dunkley; J Kung; R C Scott; P Nicolaides; B Neville; S E Aylett; W Harkness; J H Cross Journal: Epilepsy Res Date: 2010-12-14 Impact factor: 3.045
Authors: Leslie E Grayson; Jurriaan M Peters; Tarrant McPherson; Darcy A Krueger; Mustafa Sahin; Joyce Y Wu; Hope A Northrup; Brenda Porter; Gary R Cutter; Sarah E O'Kelley; Jessica Krefting; Scellig S Stone; Joseph R Madsen; Aria Fallah; Jeffrey P Blount; Howard L Weiner; E Martina Bebin Journal: Pediatr Neurol Date: 2020-04-14 Impact factor: 3.372
Authors: Jonathan Roth; Shlomi Constantini; Margaret Ekstein; Howard L Weiner; Manjari Tripathi; Poodipedi Sarat Chandra; Massimo Cossu; Michele Rizzi; Robert J Bollo; Hélio Rubens Machado; Marcelo Volpon Santos; Robert F Keating; Chima O Oluigbo; James T Rutka; James M Drake; George I Jallo; Nir Shimony; Jeffrey M Treiber; Alessandro Consales; Francesco T Mangano; Jeffrey H Wisoff; Eveline Teresa Hidalgo; William E Bingaman; Ajay Gupta; Gozde Erdemir; Swetha J Sundar; Mony Benifla; Vladimir Shapira; Sandi K Lam; Aria Fallah; Cassia A B Maniquis; Martin Tisdall; Aswin Chari; Giuseppe Cinalli; Jeffrey P Blount; Georg Dorfmüller; Shimrit Uliel-Sibony Journal: Epilepsia Date: 2021-06-14 Impact factor: 5.864